RTS,S/AS01E

PreclinicalBiologic

GSK

RTS,S/AS01E is one of 20 biologic programs targeting Malaria. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MalariaActive, not recruiting

MalariaPreclinical

Active, not recruiting

Competition

Competitive Landscape

479 competitors in Malaria

#DrugCompanyPhaseTrials

Biltricide

Bayer

Preclinical

1 2

Stelara

Johnson & Johnson

Preclinical

—3

Hydroxychloroquine Sulfate

Novartis

Preclinical

—4

Iron

WWatson Pharmaceuticals

Preclinical

1 5

IV LBH589

Novartis

Preclinical

1 6

Mefloquine Plus Artesunate

Medicines for Malaria Venture

Preclinical

1 7

IV Ceftriaxone

RRESnTEC, Institute of Research

Preclinical

1 8

Malarone

Medicines for Malaria Venture

Preclinical

3 9

Piperaquine

UUniversity of Oxford

Preclinical

3 10

Albendazole and Praziquantel

UUniversidad Peruana Cayetano Heredia

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Malaria4 trials

A Study to Evaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Challenge Model of a Fractional Booster Dose of GSK Biologicals' Candidate Malaria Vaccine Administered to Previously Vaccinated Healthy Malaria-naïve Adults

Completed· GSK logo

GSK·Phase 2·NCT03824236·61 enrolled

Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age

Completed· GSK logo

GSK·Phase 2·NCT03276962·1,500 enrolled

An Extended Follow up of a RTS,S/AS01E Malaria Vaccine Trial

Unknown status·KKEMRI-Wellcome Trust Collaborative Research Program··NCT00872963·450 enrolled

Show 1 more trial

Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults

Completed· GSK logo

GSK·Phase 2·NCT03162614·154 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for RTS,S/AS01E. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RTS,S/AS01E compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RTS,S/AS01E. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: GSK

RTS,S/AS01E

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Malaria4 trials

References

Drug Info

Quick Facts

Related News